Supply Chain Ecosystem Analysis now part of DBMR Reports
Market Size in USD Billion
| 2024 –2031 | |
|
|
USD 1.55 Billion |
| USD 5.21 Billion | |
| % | |
|
The Global Brain Cancer Diagnostic Market was valued at USD 1.55 billion in 2023. The market size is growing at the CAGR of 18.90 % and projected to reach USD 5.21 billion by 2031.
Get Exclusive Sample Copy of this Report Here
An aberrant and unchecked cell proliferation in the brain is called a brain tumor. It might be benign or cancerous. Brain tissue gives rise to brain tumors, which hardly ever spread. Eventually, the tumor compresses other brain structures, causing damage. The American Brain Tumor Association (ABTA) distinguishes between primary and secondary brain tumors. Brain tissue gives rise to primary tumors, while other body parts give rise to secondary tumors that eventually spread to the brain.
Data Bridge Market research market report provides details of recent developments, trade regulations, market share, market trends on the basis of its segmentations and regional analysis, impact of market players, analysis of opportunities in terms of emerging revenue pockets, market regulations, strategic market growth analysis, market size, category wise market growths, application niches and dominance, product approvals, product launches, geographic expansions, and technological innovations in the market. To gain more info on the market, contact Data Bridge Market Research’s team of expert analysts. Our team will help you make informed market decisions to achieve business growth.
|
Global Brain Cancer Diagnostic Market Report Metric Details
|
|
|
Forecast Period
|
2024-2031
|
|
Base Year
|
2023
|
|
Historic Year
|
2022 (Customizable 2016-2021)
|
|
Measuring Unit
|
USD Billion
|
|
Data Pointer
|
Market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
The most prevalent kind of primary tumor originating from the glial tissue of the brain is a glioma. Comparing glioblastoma multiform to other tumors, it is of a higher grade and grows more quickly. There are cutting-edge drugs available to treat brain tumors. Over the projected period, rising pharmaceutical R&D spending is anticipated to fuel profitable growth in the worldwide brain tumor treatment market. Data Bridge Market Research took a dive into comprehensively analyzing the market and unveiled that the Global Brain Cancer Diagnostic Market is increasing at a CAGR of 18.90 %. The size of the market is valued at USD 1.55 billion in 2023 and is expected to grow up to USD 5.21 billion by 2031.
Global Brain Cancer Diagnostic Market Growth Drivers
Peptide-Based Therapies
Peptide-based drug delivery systems have been introduced as a result of the success of peptide-based therapeutics, which was first shown by insulin treatments. This has had a significant impact on the cancer care market. Peptide medicines have been used much more frequently in cancer treatment and diagnosis in recent years, and their use in chemotherapy regimens has increased significantly. By improving the efficacy of cancer therapies, this integration propels additional developments and expansion in the peptide-based cancer therapeutics market.
Diverse Nature of Gliomas
Gliomas represent a heterogeneous class of glial cell-derived brain tumors, and their intricate nature presents formidable obstacles to both diagnosis and management. Their growth patterns, clinical behaviors, and molecular characteristics differ greatly amongst them. From low-grade, slowly growing tumors to high-grade, aggressive forms like glioblastomas, gliomas can take many different forms. Each tumor is distinct due to its diversity, which includes variations in genetic mutations, epigenetic changes, and histological characteristics. Because gliomas are heterogeneous, specific diagnostic techniques and individualized treatment plans are necessary. A one-size-fits-all approach is frequently insufficient to meet the unique requirements of each patient and tumor type.
R&D Investments Drives Market Growth
The increased need for efficient diagnosis and treatment is largely being driven by the growing incidence of brain tumors. The American Society of Clinical Oncology (ASCO) reports that the annual number of new cases of primary brain cancer diagnosed in the United States alone is 22,850, representing a 2.6% increase in the incidence rate of brain tumors over the previous year. The need for cutting-edge diagnostic methods and treatment options catered to this growing patient population is growing as a result of the increase in cases and the aging population, who are more vulnerable to brain tumors.
Telemedicine Transforming Brain Cancer
By enabling remote consultations and diagnostic services, advancements in telemedicine are revolutionizing the diagnosis of brain cancer. This is especially helpful for underprivileged and rural areas that have limited access to specialized care. Patients can obtain professional assessments, imaging analyses, and diagnostic interpretations from top specialists virtually through telemedicine platforms. In addition to ensuring prompt and equitable care for patients with brain cancer, this remote accessibility broadens the scope of diagnostic services, spurring market expansion and enhancing patient outcomes in previously underserved areas.
Artificial Intelligence Integration
Using machine learning and artificial intelligence (AI) to evaluate imaging data and forecast tumor behavior greatly improves the accuracy and efficiency of brain cancer diagnosis. Artificial intelligence (AI) algorithms have the ability to process and interpret complex imaging data more quickly and accurately than traditional methods. They can also spot subtle patterns and anomalies that human reviewers might overlook. This technology allows for more accurate predictions of tumor progression and treatment response, in addition to increasing the accuracy of tumor detection and characterization. Consequently, the market for brain cancer diagnostics is experiencing growth and innovation due to the possibility of earlier and more customized interventions provided by AI-driven diagnostic solutions.
Patient Variability
The process of accurately diagnosing and effectively treating brain tumors is complicated by their heterogeneous nature, which includes their diverse types, varying molecular characteristics, and variability in how individual patients respond to diagnostic tests. It is challenging to develop universal diagnostic solutions that are efficient for every patient because of this complexity. Variability in tumor appearance on imaging, response to molecular testing, and response to treatment can result from tumor variability, which calls for individualized approaches and specialized diagnostic techniques to guarantee precise and customized care.
Shortage of Skilled Professionals
The broad adoption of state-of-the-art diagnostic technologies is hampered by a severe shortage of qualified personnel, particularly in developing nations, who can operate sophisticated diagnostic equipment and interpret complex data. The ability to use sophisticated equipment like high-resolution MRI machines and sophisticated molecular diagnostic systems, as well as to analyze complex imaging and genetic data, is hampered by a shortage of qualified personnel. As a result, this shortage makes it more difficult to apply the most recent diagnostic developments in these fields, worsening healthcare quality disparities and limiting access to the best brain cancer diagnosis.
High Cost of Diagnosis Tools
Advanced diagnostic technologies, like molecular diagnostics and high-resolution MRI, are expensive, which makes it difficult for them to be widely adopted, particularly in developing and low-income countries. The significant equipment and ongoing maintenance costs associated with these technologies may be unaffordable for healthcare systems with tight budgets. Because of this, many areas with limited funding find it difficult to obtain and apply these cutting-edge diagnostics, which causes differences in the accessibility of sophisticated tools for diagnosing brain cancer and lowers the standard of care overall.
Regulatory Hurdles
New brain cancer diagnostic technologies must go through a lengthy and complicated regulatory approval process that includes numerous clinical trials, data submissions, and regulatory body reviews. This drawn-out process, which requires businesses to navigate strict requirements and address multiple regulatory concerns, can delay the market entry of innovative solutions and significantly increase development costs. Delays in approval can impede the timely provision of sophisticated diagnostic instruments, thereby impeding their timely reach to patients and healthcare providers. This could also impede the overall growth of the market and hinder the progress made in brain cancer diagnosis.
|
Global Brain Cancer Diagnostic Market Segmentations Overview
|
|
|
Segments Type
|
Sub-Segments
|
|
Test Type
|
Imaging Test, Biopsy, Lumbar Puncture, Molecular Testing, Electroencephalography, Others
|
|
Cancer Type
|
Acoustic Neuroma, Astrocytomas, Glioblastoma Multiforme, Meningiomas, Oligodendroglioma, Others
|
|
Age Group
|
Below 21, 21-34, 35-65, 65 and above
|
|
End-user
|
Hospitals, Specialty Clinics, Diagnostic Centers & Research Institutes, Ambulatory Surgical Centers, Others
|
Key Insight
|
Global Brain Cancer Diagnostic Market Regional Overview
|
|
|
Regions
|
Countries
|
|
Europe
|
Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe
|
|
APAC
|
China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific
|
|
North America
|
U.S., Canada, and Mexico
|
|
MEA
|
Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East, and Africa
|
|
South America
|
Brazil, Argentina, and Rest of South America
|
Key Insights
Global Brain Cancer Diagnostic Market Leading Players
DBMR’s market report on Global Brain Cancer Diagnostic Market takes you through valuable insights that can contribute to making several important business decisions. Based on our reports and research expertise you can create realistic growth strategies for your business.
SKU-
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE GLOBAL BRAIN CANCER DIAGNOSTIC MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT TYPE SEGMENT LIFELINE CURVE
2.8 DBMR MARKET POSITION GRID
2.9 VENDOR SHARE ANALYSIS
2.1 MARKET END USER COVERAGE GRID
2.11 SECONDARY SOURCES
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
5 EPIDEMIOLOGY
6 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET, INDUSTRY INSIGHT
7 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET, REGULATIONS
7.1 REGULATORY SCENARIO IN THE U.S
7.2 REGULATORY SCENARIO IN AUSTRALIA
7.3 REGULATORY SCENARIO IN JAPAN
7.4 REGULATORY SCENARIO IN CHINA
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 RISING CASES OF BRAIN CANCER WORLDWIDE
8.1.2 RISING AWARENESS OF THE EARLY DIAGNOSIS OF BRAIN CANCER
8.1.3 IMPROVED IMAGING TECHNIQUES
8.1.4 INNOVATIONS IN DRUG DELIVERY TO BRAIN CANCER CELLS
8.2 RESTRAINTS
8.2.1 HIGH COST ASSOCIATED WITH DIAGNOSIS & TREATMENT FOR BRAIN CANCER
8.2.2 SIDE EFFECTS OF BRAIN CANCER TREATMENT DRUGS & THERAPIES
8.2.3 LATE DIAGNOSIS OF BRAIN CANCER RESULTING IN POOR PROGNOSIS
8.3 OPPORTUNITIES
8.3.1 INCREASING INVESTMENT AND FUNDING BY EMERGING PLAYERS
8.3.2 GOVERNMENT INITIATIVES TOWARD CANCER DIAGNOSTIC
8.3.3 RISING HEALTHCARE EXPENDITURE
8.4 CHALLENGES
8.4.1 STRINGENT REGULATORY REQUIREMENTS FOR DIAGNOSTIC PRODUCTS
8.4.2 OPERATIONAL BARRIERS FACED IN CONDUCTING DIAGNOSTIC TESTS
9 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE
9.1 OVERVIEW
9.2 IMAGING TEST
9.2.1 CT SCAN
9.2.2 MRI
9.2.3 PET
9.2.4 OTHERS
9.3 MOLECULAR TESTING
9.4 ELECTROENCEPHALOGRAPHY (EEG)
9.5 LUMBAR PUNCTURE
9.6 BIOPSY
9.6.1 OPEN BIOPSY
9.6.2 STEREOTACTIC BIOPSY
9.6.3 NEEDLE BIOPSY
9.6.4 NEUROENDOSCOPY
9.7 OTHERS
10 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE
10.1 OVERVIEW
10.2 GLIOBLASTOMA MULTIFORME
10.3 MENINGIOMAS
10.4 ASTROCYTOMAS
10.5 ACOUSTIC NEUROMA
10.6 OLIGODENDROGLIOMA
10.7 OLIGODENDROGLIOMA
10.8 OTHERS
11 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP
11.1 OVERVIEW
11.2 35-65
11.3 65 AND ABOVE
11.4 BELOW 21
11.5 21-34
12 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET, BY END USER
12.1 OVERVIEW
12.2 HOSPITALS
12.3 SPECIALTY CLINICS
12.4 DIAGNOSTIC CENTERS & RESEARCH INSTITUTES
12.5 AMBULATORY SURGICAL CENTERS
12.6 OTHERS
13 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET, BY REGION
13.1 OVERVIEW
13.2 NORTH AMERICA
13.2.1 U.S.
13.2.2 CANADA
13.2.3 MEXICO
13.3 EUROPE
13.3.1 GERMANY
13.3.2 FRANCE
13.3.3 U.K.
13.3.4 ITALY
13.3.5 SPAIN
13.3.6 RUSSIA
13.3.7 SWITZERLAND
13.3.8 NETHERLANDS
13.3.9 TURKEY
13.3.10 BELGIUM
13.3.11 REST OF EUROPE
13.4 ASIA-PACIFIC
13.4.1 CHINA
13.4.2 JAPAN
13.4.3 INDIA
13.4.4 AUSTRALIA
13.4.5 SOUTH KOREA
13.4.6 THAILAND
13.4.7 SINGAPORE
13.4.8 INDONESIA
13.4.9 MALAYSIA
13.4.10 PHILIPPINES
13.4.11 REST OF ASIA-PACIFIC
13.5 SOUTH AMERICA
13.5.1 BRAZIL
13.5.2 ARGENTINA
13.5.3 REST OF SOUTH AMERICA
13.6 MIDDLE EAST AND AFRICA
13.6.1 SOUTH AFRICA
13.6.2 SAUDI ARABIA
13.6.3 U.A.E.
13.6.4 KUWAIT
13.6.5 EGYPT
13.6.6 REST OF MIDDLE EAST AND AFRICA
14 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: GLOBAL
14.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
14.3 COMPANY SHARE ANALYSIS: EUROPE
14.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
15 SWOT ANALYSIS
16 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET, COMPANY PROFILE
16.1 KONINKLIJKE PHILIPS N.V.
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 COMPANY SHARE ANALYSIS
16.1.4 PRODUCT PORTFOLIO
16.1.5 RECENT DEVELOPMENTS
16.2 CANON INC.
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 COMPANY SHARE ANALYSIS
16.2.4 PRODUCT PORTFOLIO
16.2.5 RECENT DEVELOPMENT
16.3 SIEMENS HEALTHCARE GMBH
16.3.1 COMPANY SNAPSHOT
16.3.2 REVENUE ANALYSIS
16.3.3 COMPANY SHARE ANALYSIS
16.3.4 PRODUCT PORTFOLIO
16.3.5 RECENT DEVELOPMENTS
16.4 BD
16.4.1 COMPANY SNAPSHOT
16.4.2 REVENUE ANALYSIS
16.4.3 COMPANY SHARE ANALYSIS
16.4.4 PRODUCT PORTFOLIO
16.4.5 RECENT DEVELOPMENTS
16.5 NIHON KOHDEN CORPORATION.
16.5.1 COMPANY SNAPSHOT
16.5.2 RECENT FINANCIALS
16.5.3 COMPANY SHARE ANALYSIS
16.5.4 PRODUCT PORTFOLIO
16.5.5 RECENT DEVELOPMENT
16.6 BIOCEPT, INC.
16.6.1 COMPANY SNAPSHOT
16.6.2 REVENUE ANALYSIS
16.6.3 PRODUCT PORTFOLIO
16.6.4 RECENT DEVELOPMENT
16.7 BIOMIND
16.7.1 COMPANY SNAPSHOT
16.7.2 PRODUCT PORTFOLIO
16.7.3 RECENT DEVELOPMENT
16.8 CEREBRAL DIAGNOSTIC
16.8.1 COMPANY SNAPSHOT
16.8.2 PRODUCT PORTFOLIO
16.8.3 RECENT DEVELOPMENT
16.9 DXCOVER LIMITED
16.9.1 COMPANY SNAPSHOT
16.9.2 PRODUCT PORTFOLIO
16.9.3 RECENT DEVELOPMENT
16.1 FONAR CORP.
16.10.1 COMPANY SNAPSHOT
16.10.2 REVENUE ANALYSIS
16.10.3 PRODUCT PORTFOLIO
16.10.4 RECENT DEVELOPMENT
16.11 FUJIFILM CORPORATION
16.11.1 COMPANY SNAPSHOT
16.11.2 REVENUE ANALYSIS
16.11.3 PRODUCT PORTFOLIO
16.11.4 RECENT DEVELOPMENT
16.12 GE HEALTHCARE.
16.12.1 COMPANY SNAPSHOT
16.12.2 REVENUE ANALYSIS
16.12.3 PRODUCT PORTFOLIO
16.12.4 RECENT DEVELOPMENT
16.13 HITACHI, LTD.
16.13.1 COMPANY SNAPSHOT
16.13.2 REVENUE ANALYSIS
16.13.3 PRODUCT PORTFOLIO
16.13.4 RECENT DEVELOPMENT
16.14 MINFOUND MEDICAL SYSTEMS CO.,
16.14.1 COMPANY SNAPSHOT
16.14.2 PRODUCT PORTFOLIO
16.14.3 RECENT DEVELOPMENT
16.15 NANTOMICS.
16.15.1 COMPANY SNAPSHOT
16.15.2 PRODUCT PORTFOLIO
16.15.3 RECENT DEVELOPMENT
16.16 NEUSOFT CORPORATION
16.16.1 COMPANY SNAPSHOT
16.16.2 REVENUE ANALYSIS
16.16.3 PRODUCT PORTFOLIO
16.16.4 RECENT DEVELOPMENT
16.17 SEQUOIA HEALTHCARE.
16.17.1 COMPANY SNAPSHOT
16.17.2 PRODUCT PORTFOLIO
16.17.3 RECENT DEVELOPMENT
16.18 STERNMED GMBH
16.18.1 COMPANY SNAPSHOT
16.18.2 PRODUCT PORTFOLIO
16.18.3 RECENT DEVELOPMENT
16.19 THERMO FISHER SCIENTIFIC INC.
16.19.1 COMPANY SNAPSHOT
16.19.2 REVENUE ANALYSIS
16.19.3 PRODUCT PORTFOLIO
16.19.4 RECENT DEVELOPMENT
16.2 TIME MEDICAL HOLDING.
16.20.1 COMPANY SNAPSHOT
16.20.2 PRODUCT PORTFOLIO
16.20.3 RECENT DEVELOPMENTS
17 QUESTIONNAIRE
18 RELATED REPORTS
TABLE 1 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 2 GLOBAL IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 3 GLOBAL IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 4 GLOBAL MOLECULAR TESTING IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 5 GLOBAL ELECTROENCEPHALOGRAPHY (EEG) IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 6 GLOBAL LUMBAR PUNCTURE IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 7 GLOBAL BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 8 GLOBAL BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 9 GLOBAL OTHERS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 10 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 11 GLOBAL GLIOBLASTOMA MULTIFORME IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 12 GLOBAL MENINGIOMAS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 13 GLOBAL ASTROCYTOMAS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 14 GLOBAL ACOUSTIC NEUROMA IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 15 GLOBAL OLIGODENDROGLIOMA IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 16 GLOBAL OTHERS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 17 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 18 GLOBAL 35-65 IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 19 GLOBAL 65 AND ABOVE IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 20 GLOBAL BELOW 21 IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 21 GLOBAL 21-34 IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 22 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 23 GLOBAL HOSPITALS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 24 GLOBAL SPECIALTY CLINICS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 25 GLOBAL DIAGNOSTIC CENTERS & RESEARCH INSTITUTES IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 26 GLOBAL AMBULATORY SURGICAL CENTERS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 27 GLOBAL OTHERS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 28 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 29 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 30 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 31 NORTH AMERICA IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 32 NORTH AMERICA BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 33 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 34 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 35 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 36 U.S. BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 37 U.S. IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 38 U.S. BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 39 U.S. BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 40 U.S. BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 41 U.S. BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 42 CANADA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 43 CANADA IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 44 CANADA BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 45 CANADA BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 46 CANADA BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 47 CANADA BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 48 MEXICO BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 49 MEXICO IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 50 MEXICO BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 51 MEXICO BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 52 MEXICO BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 53 MEXICO BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 54 EUROPE BRAIN CANCER DIAGNOSTIC MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 55 EUROPE BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 56 EUROPE IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 57 EUROPE BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 58 EUROPE BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 59 EUROPE BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 60 EUROPE BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 61 GERMANY BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 62 GERMANY IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 63 GERMANY BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 64 GERMANY BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 65 GERMANY BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 66 GERMANY BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 67 FRANCE BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 68 FRANCE IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 69 FRANCE BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 70 FRANCE BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 71 FRANCE BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 72 FRANCE BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 73 U.K. BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 74 U.K. IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 75 U.K. BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 76 U.K. BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 77 U.K. BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 78 U.K. BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 79 ITALY BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 80 ITALY IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 81 ITALY BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 82 ITALY BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 83 ITALY BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 84 ITALY BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 85 SPAIN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 86 SPAIN IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 87 SPAIN BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 88 SPAIN BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 89 SPAIN BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 90 SPAIN BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 91 RUSSIA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 92 RUSSIA IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 93 RUSSIA BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 94 RUSSIA BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 95 RUSSIA BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 96 RUSSIA BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 97 SWITZERLAND BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 98 SWITZERLAND IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 99 SWITZERLAND BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 100 SWITZERLAND BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 101 SWITZERLAND BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 102 SWITZERLAND BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 103 NETHERLANDS BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 104 NETHERLANDS IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 105 NETHERLANDS BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 106 NETHERLANDS BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 107 NETHERLANDS BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 108 NETHERLANDS BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 109 TURKEY BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 110 TURKEY IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 111 TURKEY BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 112 TURKEY BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 113 TURKEY BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 114 TURKEY BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 115 BELGIUM BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 116 BELGIUM IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 117 BELGIUM BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 118 BELGIUM BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 119 BELGIUM BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 120 BELGIUM BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 121 REST OF EUROPE BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 122 ASIA-PACIFIC BRAIN CANCER DIAGNOSTIC MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 123 ASIA-PACIFIC BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 124 ASIA-PACIFIC IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 125 ASIA-PACIFIC BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 126 ASIA-PACIFIC BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 127 ASIA-PACIFIC BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 128 ASIA-PACIFIC BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 129 CHINA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 130 CHINA IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 131 CHINA BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 132 CHINA BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 133 CHINA BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 134 CHINA BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 135 JAPAN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 136 JAPAN IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 137 JAPAN BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 138 JAPAN BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 139 JAPAN BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 140 JAPAN BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 141 INDIA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 142 INDIA IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 143 INDIA BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 144 INDIA BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 145 INDIA BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 146 INDIA BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 147 AUSTRALIA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 148 AUSTRALIA IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 149 AUSTRALIA BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 150 AUSTRALIA BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 151 AUSTRALIA BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 152 AUSTRALIA BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 153 SOUTH KOREA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 154 SOUTH KOREA IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 155 SOUTH KOREA BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 156 SOUTH KOREA BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 157 SOUTH KOREA BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 158 SOUTH KOREA BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 159 THAILAND BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 160 THAILAND IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 161 THAILAND BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 162 THAILAND BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 163 THAILAND BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 164 THAILAND BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 165 SINGAPORE BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 166 SINGAPORE IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 167 SINGAPORE BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 168 SINGAPORE BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 169 SINGAPORE BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 170 SINGAPORE BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 171 INDONESIA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 172 INDONESIA IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 173 INDONESIA BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 174 INDONESIA BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 175 INDONESIA BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 176 INDONESIA BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 177 MALAYSIA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 178 MALAYSIA IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 179 MALAYSIA BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 180 MALAYSIA BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 181 MALAYSIA BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 182 MALAYSIA BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 183 PHILIPPINES BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 184 PHILIPPINES IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 185 PHILIPPINES BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 186 PHILIPPINES BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 187 PHILIPPINES BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 188 PHILIPPINES BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 189 REST OF ASIA-PACIFIC BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 190 SOUTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 191 SOUTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 192 SOUTH AMERICA IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 193 SOUTH AMERICA BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 194 SOUTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 195 SOUTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 196 SOUTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 197 BRAZIL BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 198 BRAZIL IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 199 BRAZIL BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 200 BRAZIL BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 201 BRAZIL BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 202 BRAZIL BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 203 ARGENTINA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 204 ARGENTINA IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 205 ARGENTINA BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 206 ARGENTINA BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 207 ARGENTINA BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 208 ARGENTINA BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 209 REST OF SOUTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 210 MIDDLE EAST AND AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 211 MIDDLE EAST AND AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 212 MIDDLE EAST AND AFRICA IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 213 MIDDLE EAST AND AFRICA BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 214 MIDDLE EAST AND AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 215 MIDDLE EAST AND AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 216 MIDDLE EAST AND AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 217 SOUTH AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 218 SOUTH AFRICA IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 219 SOUTH AFRICA BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 220 SOUTH AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 221 SOUTH AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 222 SOUTH AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 223 SAUDI ARABIA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 224 SAUDI ARABIA IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 225 SAUDI ARABIA BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 226 SAUDI ARABIA BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 227 SAUDI ARABIA BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 228 SAUDI ARABIA BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 229 U.A.E. BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 230 U.A.E. IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 231 U.A.E. BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 232 U.A.E. BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 233 U.A.E. BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 234 U.A.E. BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 235 KUWAIT BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 236 KUWAIT IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 237 KUWAIT BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 238 KUWAIT BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 239 KUWAIT BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 240 KUWAIT BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 241 EGYPT BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 242 EGYPT IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 243 EGYPT BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 244 EGYPT BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 245 EGYPT BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 246 EGYPT BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 247 REST OF MIDDLE EAST AND AFRICA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
FIGURE 1 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: SEGMENTATION
FIGURE 2 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: DATA TRIANGULATION
FIGURE 3 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: DROC ANALYSIS
FIGURE 4 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS
FIGURE 5 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: DBMR POSITION GRID
FIGURE 8 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: VENDOR SHARE ANALYSIS
FIGURE 9 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: END USER COVERAGE GRID
FIGURE 10 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: SEGMENTATION
FIGURE 11 NORTH AMERICA IS ANTICIPATED TO DOMINATE THE GLOBAL BRAIN CANCER DIAGNOSTIC MARKET, AND ASIA-PACIFIC IS ESTIMATED TO BE GROWING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2023 TO 2030
FIGURE 12 RISING CASES OF BRAIN CANCER WORLDWIDE & IMPROVED IMAGING TECHNIQUES ARE EXPECTED TO DRIVE THE GLOBAL BRAIN CANCER DIAGNOSTIC MARKET FROM 2023 TO 2030
FIGURE 13 THE IMAGING TEST SEGMENT IS EXPECTED TO HAVE THE LARGEST SHARE OF THE GLOBAL BRAIN CANCER DIAGNOSTIC MARKET FROM 2023 TO 2030
FIGURE 14 ASIA –PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR FOR BRAIN CANCER DIAGNOSTIC MANUFACTURERS IN THE FORECAST PERIOD OF 2023 TO 2030
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF THE GLOBAL BRAIN CANCER DIAGNOSTIC MARKET
FIGURE 16 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE, 2022
FIGURE 17 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE 2023-2030 (USD MILLION)
FIGURE 18 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE, CAGR (2023-2030)
FIGURE 19 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE, LIFELINE CURVE
FIGURE 20 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: BY CANCER TYPE, 2022
FIGURE 21 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: BY CANCER TYPE 2023-2030 (USD MILLION)
FIGURE 22 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: BY CANCER TYPE, CAGR (2023-2030)
FIGURE 23 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: BY CANCER TYPE, LIFELINE CURVE
FIGURE 24 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: BY AGE GROUP, 2022
FIGURE 25 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: BY AGE GROUP, 2023-2030 (USD MILLION)
FIGURE 26 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: BY AGE GROUP, CAGR (2023-2030)
FIGURE 27 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: BY AGE GROUP, LIFELINE CURVE
FIGURE 28 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: BY END USER, 2022
FIGURE 29 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 30 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: BY END USER, CAGR (2023-2030)
FIGURE 31 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: BY END USER, LIFELINE CURVE
FIGURE 32 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: SNAPSHOT (2022)
FIGURE 33 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: BY REGION (2022)
FIGURE 34 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: BY REGION (2023 & 2030)
FIGURE 35 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: BY REGION (2022 & 2030)
FIGURE 36 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE (2023-2030)
FIGURE 37 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: SNAPSHOT (2022)
FIGURE 38 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: BY COUNTRY (2022)
FIGURE 39 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: BY COUNTRY (2023 & 2030)
FIGURE 40 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: BY COUNTRY (2022 & 2030)
FIGURE 41 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE (2023-2030)
FIGURE 42 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: SNAPSHOT (2022)
FIGURE 43 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: BY COUNTRY (2022)
FIGURE 44 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: BY COUNTRY (2023 & 2030)
FIGURE 45 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: BY COUNTRY (2022 & 2030)
FIGURE 46 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE (2023-2030)
FIGURE 47 ASIA-PACIFIC BRAIN CANCER DIAGNOSTIC MARKET: SNAPSHOT (2022)
FIGURE 48 ASIA-PACIFIC BRAIN CANCER DIAGNOSTIC MARKET: BY COUNTRY (2022)
FIGURE 49 ASIA-PACIFIC BRAIN CANCER DIAGNOSTIC MARKET: BY COUNTRY (2023 & 2030)
FIGURE 50 ASIA-PACIFIC BRAIN CANCER DIAGNOSTIC MARKET: BY COUNTRY (2022 & 2030)
FIGURE 51 ASIA-PACIFIC BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE (2023-2030)
FIGURE 52 SOUTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: SNAPSHOT (2022)
FIGURE 53 SOUTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: BY COUNTRY (2022)
FIGURE 54 SOUTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: BY COUNTRY (2023 & 2030)
FIGURE 55 SOUTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: BY COUNTRY (2022 & 2030)
FIGURE 56 SOUTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE (2023-2030)
FIGURE 57 MIDDLE EAST AND AFRICA BRAIN CANCER DIAGNOSTIC MARKET: SNAPSHOT (2022)
FIGURE 58 MIDDLE EAST AND AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY COUNTRY (2022)
FIGURE 59 MIDDLE EAST AND AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY COUNTRY (2023 & 2030)
FIGURE 60 MIDDLE EAST AND AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY COUNTRY (2022 & 2030)
FIGURE 61 MIDDLE EAST AND AFRICA BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE (2023-2030)
FIGURE 62 GLOBAL BRAIN CANCER DIAGNOSTIC MARKET: COMPANY SHARE 2022 (%)
FIGURE 63 NORTH AMERICA BRAIN CANCER DIAGNOSTIC MARKET: COMPANY SHARE 2022 (%)
FIGURE 64 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: COMPANY SHARE 2022 (%)
FIGURE 65 ASIA-PACIFIC BRAIN CANCER DIAGNOSTIC MARKET: COMPANY SHARE 2022 (%)
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.